Recent Updates
Recently added Catalysts
MLTX Negative Sentiment Score: 25/100

MoonLake Immunotherapeutics Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights – MLTX

Key Takeaway: MoonLake Immunotherapeutics (MLTX) has been hit with a class action securities lawsuit alleging securities fraud, affecting investors between March 10, 2024, and September 29, 2025. The complaint claims that MoonLake made misleading statements regarding its drug candidate SLK, suggesting it would provide superiority over traditional monoclonal antibodies, which has been challenged by the lawsuit. Investors have until December 15, 2025, to participate in the legal process and may recover losses without upfront costs.

Market Sentiment Analysis

CONCERNS & RISKS

  • MoonLake Immunotherapeutics is facing a class action lawsuit for securities fraud.
  • The lawsuit alleges false statements about their drug candidate, SLK.
  • Investors are at risk of financial losses due to the lawsuit's claims.

Full Press Release Details

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team:
MLTX investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) It's sole drug candidate, SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) SLK’s distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK’s distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements regarding SLK’s purported superiority to monoclonal antibodies.
WHAT'S NEXT? If you suffered a loss in MoonLake during the relevant time frame, you have until December 15, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the MoonLake Immunotherapeutics lawsuit about?

The lawsuit addresses alleged securities fraud impacting MoonLake investors from March 10, 2024, to September 29, 2025.

What are the main allegations in the lawsuit?

Defendants allegedly made false statements about the superiority of MoonLake's drug candidate, SLK, compared to BIMZELX.

How can MoonLake investors join the lawsuit?

Investors can request to be lead plaintiffs until December 15, 2025, without needing to incur costs.

What does it cost to participate in the lawsuit?

Participation in the lawsuit is free for class members, with no out-of-pocket costs.

Why choose Levi & Korsinsky for legal representation?

Levi & Korsinsky has extensive experience and a strong track record in securities litigation.

Last updated: Oct 28, 2025